Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

November 3, 2022

Novel Drug to Be Investigated for Breast Cancer Treatment-Related Hot Flashes

Author(s):

Brielle Benyon

Patients with breast cancer can enroll on a clinical trial analyzing elinzanetant for endocrine therapy-related hot flashes.

An expanded clinical trial called OASIS 4 will investigate a new drug, elinzanetant, in treating vasomotor symptoms (hot flashes) in women with breast cancer undergoing endocrine therapy.

According to Bayer, the manufacturer of elinzantant, hot flashes affect up to 80% of women who are undergoing menopause and can have negative effects of quality of life. When treatments such as endocrine therapy may be contributing to this side effect, patients may be less likely to take their drugs as prescribed, Bayer said in a press release.

Endocrine therapy is a common treatment method for patients with hormone-receptor—positive disease. The treatment’s goal is to reduce hormone levels, which can result in feelings of night sweats, hot flashes and vaginal dryness.

READ MORE: Breast Cancer Treatments Propel Many Women Into 'Rapid, Dramatic' Medical Menopause

“For women treated with endocrine therapy for breast cancer — potentially for numerous years — vasomotor symptoms can intensively affect their quality of life and treatment continuation, which in turn might impact the effectiveness of their cancer therapy and hence their survival”, said Dr. Christian Rommel, member of the executive committee of Bayer AG’s Pharmaceutical Division and global head of Research and Development, in the release.

OASIS 4 will be an added component to the currently ongoing phase 3 trial of elinzanetant in menopausal women without breast cancer.

Researchers plan on enrolling approximately 400 patients in the global. Some will be randomly assigned to receive 120 mg daily of elinzanetant, while others will receive a placebo.

The main goal of the study is to determine an average change in the frequency of moderate to severe hot flashes from the start of treatment until weeks 4 and 12.

Researchers also plan to analyze the average change in severity of moderate to severe hot flashes from baseline to weeks 4 and 12; average change in frequency of moderate to severe hot flashes from baseline to week 1; change in frequency of moderate to severe hot flashes over time; average change in sleep disturbances over 12 weeks; and average change in menopause-related quality of life over 12 weeks, according to the study’ listing on clinicaltrials.gov.

To be eligible for the trial, patients must be diagnosed with hormone-receptor—positive breast cancer or be at risk for developing the disease. Those with cancer must be taking tamoxifen or an aromatase inhibitor and are expected to stay on their therapy throughout the trial.

Researchers are still recruiting participants for OASIS 4, and study data is expected to come out in December 2024.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Related Content
Advertisement
Patti McGee is an author, a massage therapist and breast cancer survivor of 20 years. Catch up on all of Patti's blogs here!
July 31st 2025

Building My Medical Team and Support System After a Cancer Diagnosis

Patti McGee
After my cancer diagnosis, I built a strong medical team and support system that helped me heal; reaching out and accepting help made all the difference.
cancer horizons podcast logo: a white microphone on a blue background
July 31st 2025

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Bonnie Annis is a breast cancer survivor, diagnosed in 2014 with stage 2b invasive ductal carcinoma with metastasis to the lymph nodes. Catch up on all of Bonnie's blogs here!
July 31st 2025

True Life Stories About Cancer Can Inspire Others

Bonnie Annis
Watching a true-life story about a woman’s battle with cancer has given me a new perspective on life.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
July 31st 2025

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of Woman.
July 31st 2025

My Passion for Guiding Women With Cancer to Embracing the ‘New You’

Patti McGee
Cancer changed my life and inspired me to guide other women in healing, self-love and rediscovering their strength through massage and coaching.
Gedatolisib combo improved PFS in patients with advanced breast cancer after prior therapies: © stock.adobe.com.
July 31st 2025

Gedatolisib Triplet Boosts Progression-Free Survival in Breast Cancer

Spencer Feldman
Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer after prior therapies.
Related Content
Advertisement
Patti McGee is an author, a massage therapist and breast cancer survivor of 20 years. Catch up on all of Patti's blogs here!
July 31st 2025

Building My Medical Team and Support System After a Cancer Diagnosis

Patti McGee
After my cancer diagnosis, I built a strong medical team and support system that helped me heal; reaching out and accepting help made all the difference.
cancer horizons podcast logo: a white microphone on a blue background
July 31st 2025

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Bonnie Annis is a breast cancer survivor, diagnosed in 2014 with stage 2b invasive ductal carcinoma with metastasis to the lymph nodes. Catch up on all of Bonnie's blogs here!
July 31st 2025

True Life Stories About Cancer Can Inspire Others

Bonnie Annis
Watching a true-life story about a woman’s battle with cancer has given me a new perspective on life.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
July 31st 2025

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of Woman.
July 31st 2025

My Passion for Guiding Women With Cancer to Embracing the ‘New You’

Patti McGee
Cancer changed my life and inspired me to guide other women in healing, self-love and rediscovering their strength through massage and coaching.
Gedatolisib combo improved PFS in patients with advanced breast cancer after prior therapies: © stock.adobe.com.
July 31st 2025

Gedatolisib Triplet Boosts Progression-Free Survival in Breast Cancer

Spencer Feldman
Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer after prior therapies.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.